GETEC becomes new owner and operator of the Life-Science-Park Rheintal in Stein

Stein (Aargau)/Magdeburg (DE), August 22, 2023 – The Life-Science-Park Rheintal, located in the Canton of Aargau, is a renowned hub for research, development, and innovation in the field of life sciences and healthcare. With state-of-the-art facilities and outstanding expertise, the park has gained international recognition. In addition to the GETEC PARK.SWISS located in Muttenz (Canton of Baselland), the Life-Science-Park Rheintal will already be the second industrial park operated by GETEC in Switzerland. The parties have agreed not to disclose the financial details of the transaction.


As part of the GETEC Group's internationalization strategy, the acquisition of the Life-Science-Park represents an important milestone. “The acquisition of the park is an important corporate strategic step for GETEC. We are thus strengthening our activities in the European market and significantly expanding our competencies for the chemical and pharmaceutical industry. Novartis has created a top industrial location in the Life-Science-Park Rheintal and has established well-known companies here in addition to significant own activities. We would like to continue and expand this successful development,” says Pierre-Alain Graf, CEO of GETEC Group.


For the established companies, the park offers comprehensive services in the areas of building management, energy supply, engineering, maintenance, logistics, and environmentally friendly wastewater treatment and waste disposal. Here, quality, competitive costs, and sustainability play a decisive role. The Life-Science-Park Rheintal will be developed into a first-class location for international companies due to the variety of green energy and infrastructure services. GETEC not only supports the established companies of the pharmaceutical and chemical industry in reducing their carbon footprint, but also the canton in achieving its climate goals. GETEC is developing the location into an environmentally conscious competence cluster with a clear commitment to sustainable and at the same time economic action.


“The increasing complexity of demanding ESG goals, a reliable energy supply, and legal regulations, especially for utilities, is one of the most pressing challenges for the industry. We take care of these so that our customers can focus on their core business. In the Life-Science-Park Rheintal, we can holistically implement our entire know-how in the areas of energy management, digitization, sustainability, financing, and profitability in one of the most attractive life science regions in the world and thus make a significant contribution to the economic development of the region and our customers,” says Urs Zimmerli, CEO of the GETEC Switzerland Platform.


As the largest tenant, Novartis will continue to produce medicines and therapies on the premises of the Life-Science-Park Rheintal. As part of the transaction, Novartis plans to fully transfer real estate and infrastructure-related assets and services to GETEC by the end of Q4 2023. In connection with the transaction, 25 employees of Novartis in the area of services and infrastructure are expected to transfer to GETEC.
The location offers an ideal innovative environment, access to highly qualified employees from the region and large expansion reserves. In total, almost 2,000 employees of pharmaceutical and biotechnology companies are employed on the site in the areas of research, development, and production. In addition to Novartis, the chemical and pharmaceutical company Lonza and the international biotechnology company Celonic are located in the park. About one third of the area of the Life-Science-Park Rheintal, founded in 2021, is currently unused.

You can find image material of GETEC here.

You can find image material of the Life-Science-Park Rheintal here.

Your Contact